No genetic basis is identified in the available packet data, and no inheritance pattern is listed. The disease definition identifies microscopically inflammatory features at sites of hair loss, consistent with an inflammatory process. The etiology is not further characterized in genetic or mechanistic terms within this packet.

Diagnosis of alopecia areata is based on the characteristic presentation of patchy hair loss with inflammatory features identifiable at the microscopic level. Detailed diagnostic criteria beyond these defining characteristics are not available in this packet.

Triamcinolone acetonide (KENALOG-10) is listed as an FDA-approved treatment for alopecia areata in this packet, with an active market status and NDA approval. Trafermin in combination with plasma and platelet-rich plasma has received orphan drug designation for alopecia areata in pediatric patients and remains under investigation. Additional treatment options are not enumerated in this packet.

Prognosis and natural history data for alopecia areata are not present in this packet.

Alopecia areata has a highly active research landscape, with numerous ongoing clinical trials. Among the studies documented in this packet are Phase 3 trials evaluating agents including upadacitinib and ritlecitinib for severe and moderate alopecia areata, as well as Phase 1 and Phase 2 investigations of additional pharmacological approaches. The published literature encompasses approximately 330 classified studies, with review and meta-analysis articles constituting a substantial proportion. Biomarker research is also represented in the literature.